Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk | Zendy

Seth Inzaule | Zendy; Paul J. Weidle | Zendy; Chunfu Yang | Zendy; Kenneth Ndiege | Zendy; Raph L Hamers | Zendy; Tobias F. Rinke de Wit | Zendy; Timothy K. Thomas | Zendy; Clement Zeh | Zendy

Open Access

Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk

Author(s) -

Seth Inzaule,

Paul J. Weidle,

Chunfu Yang,

Kenneth Ndiege,

Raph L Hamers,

Tobias F. Rinke de Wit,

Timothy K. Thomas,

Clement Zeh

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw039

Subject(s) - stavudine , nevirapine , lamivudine , zidovudine , didanosine , nelfinavir , virology , medicine , resistance mutation , efavirenz , drug resistance , viral load , zalcitabine , biology , viral disease , reverse transcriptase , human immunodeficiency virus (hiv) , virus , polymerase chain reaction , microbiology and biotechnology , antiretroviral therapy , hepatitis b virus , gene , biochemistry

K65R is a relatively rare drug resistance mutation (DRM) selected by the NRTIs tenofovir, didanosine, abacavir and stavudine and confers cross-resistance to all NRTIs except zidovudine. Selection by other NRTIs is uncommon.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research